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Research waste in diagnostic trials: a
methods review evaluating the reporting
of test-treatment interventions
Lavinia Ferrante di Ruffano1, Jacqueline Dinnes1, Sian Taylor-Phillips1,2, Clare Davenport1, Chris Hyde3
and Jonathan J. Deeks1*
Abstract
Background: The most rigorous method for evaluating the effectiveness of diagnostic tests is through
randomised trials that compare test-treatment interventions: complex interventions comprising episodes of
testing, decision-making and treatment. The multi-staged nature of these interventions, combined with the
need to relay diagnostic decision-making and treatment planning, has led researchers to hypothesise that
test-treatment strategies may be very challenging to document. However, no reviews have yet examined the
reporting quality of interventions used in test-treatment RCTs. In this study we evaluate the completeness of
intervention descriptions in a systematically identified cohort of test-treatment RCTs.
Methods: We ascertained all test-treatment RCTs published 2004–2007, indexed in CENTRAL. Included trials randomized
patients to diagnostic tests and measured patient outcomes after treatment. Two raters examined the completeness of
test-treatment intervention descriptions in four components: 1) the test, 2) diagnostic decision-making, 3) management
decision-making, 4) treatments.
Results: One hundred and three trials compared 105 control with 119 experimental interventions, most
commonly in cardiovascular medicine (35, 34%), obstetrics and gynecology (17%), gastroenterology (14%) or
orthopedics (10%). A broad range of tests were evaluated, including imaging (50, 42%), biochemical assays
(21%) and clinical assessment (12%). Only five (5%) trials detailed all four components of experimental and
control interventions, none of which also provided a complete care pathway diagram. Experimental arms were
missing descriptions of tests, diagnostic-decision making, management planning and treatments (36%, 51%, 55% and
79% of trials respectively); control arms were missing the same details in 61%, 66%, 67% and 84% of trials.
Conclusion: Reporting of test-treatment interventions is very poor, inadequate for understanding the results of these
trials, and for comparing or translating results into clinical practice. Reporting needs to improve, with greater emphasis on
describing the decision-making components of care pathways in both pragmatic and explanatory trials.
Please see the companion paper to this article: http://bmcmedresmethodol.biomedcentral.com/articles/10.1186/
s12874-016-0287-z.
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Background
Healthcare interventions need to be described with
adequate detail in reports of randomized controlled trials
(RCTs) to allow clinicians and other decision-makers to
implement effective interventions reliably [1], whilst enab-
ling researchers to understand why an intervention may
not have been successful. Inadequate intervention descrip-
tions also hinder our ability to examine the validity of
trials, and accurately determine their eligibility for inclu-
sion in systematic reviews. Yet a growing number of
reviews find that interventions are often very poorly
described [2–7].
Guidelines detailing reporting standards for protocols
and final reports of RCTs provide some guidance on de-
scribing study interventions. Adequate reporting of trial
interventions has been widely encouraged since 2001 [8],
the most recent guidance from CONSORT [9] (Consoli-
dated Standards of Reporting of Trials, item 5) and
SPIRIT [10] (Standard Protocol Items: Recommendations
for Interventional Trials, item 11) recommends that trial
protocols and reports should describe “interventions for
each group with sufficient detail to allow replication,
including how and when they will be administered”. Most
recently, the TIDieR initiative (Template for Intervention
Description and Replication) has introduced a checklist
extension to SPIRIT and CONSORT to help researchers
to more fully describe interventions, with the ultimate aim
of improving their replicability [11].
Complex interventions have the added challenge of
multiple interacting components, each of which needs to
be described in adequate detail to allow replication. Some
fields, such as physiotherapy and psychology, document
standardized interventions in treatment manuals, however,
a recent review of 137 nonpharmacologic RCTs found that
such materials are infrequently (47%) published [4].
Studies comparing the reporting quality of pharma-
ceutical with nonpharmacologic interventions have
concluded that complex interventions are particularly
difficult to describe, standardize, reproduce and admi-
nister consistently [2, 6, 12].
Randomized trials evaluating the effects of diagnostic
tests on patient outcomes are widely heralded as the most
rigorous method for evaluating the effectiveness of tests
[13–15]. They evaluate complex interventions comprising
steps of testing, decision-making and treatment. Notably,
each patient does not receive the same treatment: rather
the treatment choice is personalized by decision-making
incorporating the results of the tests obtained in the first
step with existing diagnostic information, additional testing,
and the preferences and values of patients and clinicians, all
within the context of a particular health setting. Test-treat
interventions can be evaluated in various study designs
[16]. RCTs are not always necessary, and are often expen-
sive and difficult to undertake. Our companion review of
the methodological quality of the trials in this cohort indi-
cates that they suffer inherent methodological challenges
and are often at risk of bias due to poor methodological
quality [17].
A description of a test-treatment strategy thus involves
four main steps: 1) a test is undertaken; 2) the test result
is used (often with other information) to place patients
into diagnostic categories; 3) a management plan is deter-
mined for patients in each category; 4) the treatments are
delivered. For example, a trial may investigate whether
abdominal computed tomography (CT) in patients
presenting with suspected acute appendicitis improves
patient outcomes (Fig. 1) [18]. The complex intervention
being trialed includes: 1) a CT scan; 2) categorizing each
patient according to features observed alongside existing
diagnostic information into different diagnostic groups
(such as highly likely appendicitis, possibly appendicitis,
urinary tract infection, gastroenteritis, or ectopic preg-
nancy); 3) making a management plan for patients in each
group (such as immediate surgery, watch and wait,
antibiotics); 4) delivering the treatments.
Diagnostic and therapeutic decision-making are re-
nowned for being highly variable: the interpretation of
test results is likely to differ according to expertise [19, 20],
clinicians have individual attitudes to the balance of risks
resulting from missing diagnoses or over-treating patients
[21], while patients have highly variable attitudes and
perceptions toward their management [22, 23]. Small-scale
observations have reported a common lack of intervention
detail, particularly for the decision-making elements of test-
treatment strategies [24–26]. Consequently, researchers
have hypothesized that test-treatment strategies may be
very challenging to document [16, 25, 27, 28]. However, no
reviews have yet examined the reporting quality of inter-
ventions used in test-treatment RCTs.
In this study we evaluate the quality of reporting of
test-treatment interventions in a systematically identified
cohort of trials of diagnostic tests to determine reporting
rates for each component of the experimental and
control interventions.
Methods
Search
We searched the Cochrane Central Register of
Controlled Trials (CENTRAL, Issue 2 2009) for test-
treatment RCTs that were published between 2004
and 2007 using a validated, previously published
strategy [29] developed by information specialists
comprising general diagnostic and methodology
terms (Table 1). CENTRAL was used because it in-
cludes all reports of RCTs indexed as study types in
MEDLINE and identified from systematic, sensitive
searches of both MEDLINE and EMBASE, additional
hand-searched material, and other extensive database
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searches contributed through the Cochrane specialized
registers.
Study selection
Eligible trials randomized patients between diagnostic
testing strategies and measured at least one patient out-
come occurring after treatment. We excluded trials evalu-
ating tests for screening and monitoring, and non-English
language studies. Duplicate records were identified using
title-based sorting in Microsoft Access, and during full-
text screening. Multiple publications relating to a single
trial were assimilated through cross-referencing, with
all material used for analysis. Titles and abstracts of
potentially relevant studies were screened by one author
(LFR) and full-text reports of relevant abstracts reviewed
to determine inclusion. A random 10% sample of citations
was screened independently by a second author (CD) to
measure the reliability of the screening process [29]. Dis-
crepancies in the relevance of full articles were discussed
and resolved by consensus.
Data extraction and analysis
Trials were classified by journal type (general medical
journals, publishing on any medical topic, vs specialist
journals), trial design, clinical specialty and care setting.
Test-treatment strategies were classified according to
the diagnostic technologies evaluated and the type of
diagnostic comparison, namely whether a new test was
compared to an existing test, (‘replacement’ comparison),
used to filter which patients should receive an existing
test, (‘triage’ comparison), or added to an existing testing
strategy (‘add-on’ comparison). Experimental study
groups were defined by specific reference to a new test
to be introduced under evaluation. Control arms were
identified when referred to as the comparator, current
care standard or common clinical practice. In a minority
of cases (7/103, 7%), the control arm was identified
implicitly by the manner in which study results were
discussed.
Table 1 Search strategy for test-treatment RCTs
Search strategy Hits
#1 Sensitiva or diagnose or diagnosis or diagnostica
in Clinical Trials
70,052
#2 Randoma in Clinical Trials 335,175
#3 “Study design” next “rct” in Clinical Trials 150,275
#4 (#2 OR #3) 449,453
#5 (#1 AND #4) 50,419
#6 (#5), from 2004 to 2007 12,892
CENTRAL Issue 2 2009 (Wiley InterScience, searched 29 May 2009)–general
diagnosis textwords across all fields limited to publication years 2004 to 2007
aDenotes truncation of search term
Fig. 1 The four steps of a test-treatment strategy using abdominal CT to diagnose appendicitis in patients presenting with right lower quadrant
abdominal pain. The trial compared two diagnostic strategies for confirming or ruling out suspected acute appendicitis in adults presenting to
the emergency department with right lower quadrant abdominal pain [18]. The routine approach of scanning all such patients with CT was
compared with a new strategy of ordering CT only when indicated by specific signs and symptoms. In both arms the 4 test-treatment steps
consist of testing (routine laboratory tests +/− a CT scan), a diagnostic decision (appendicitis, other disease, no disease), a management plan for
each group (surgery or antibiotics to treat appendicitis, discharge for disease free patients, and treatment as necessary for alternative conditions),
and delivery of these treatments. The trial’s primary outcome measured the proportion of removed appendices that were disease-free
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We appraised written descriptions of intended test-
treatment strategies in four components. We defined
these components using published frameworks that out-
line which essential elements of test-treat pathways lead
to changes in patient health. These commonly present
three steps: information, decision, and action [30, 31],
which recently have been extended [23] to fully separate
the process of diagnosis from that of subsequent treat-
ment. The resulting four components are: 1) The Test:
what diagnostic test was given and how was it performed?
2) Diagnostic decision-making: how was the output from
the test categorized and used to define diagnostic groups?
3) Management decision-making: how was each diagnos-
tic group managed? 4) The Treatment: what interventions
were given and how?
Reporting of each component was assessed as present or
absent. A component was judged as reported if any descrip-
tion was provided or cited in any publications reporting on
a given trial. This included related publications not identi-
fied by the project search (e.g., design protocols, original
trial reports, long-term follow-up papers), that were traced
through citations and author-title searches of Medline. We
also systematically retrieved the full text of cited descrip-
tions to check whether citations were relevant. We did not
require descriptions to be sufficient to allow the replication
of interventions, as required by CONSORT or TIDier;
therefore while our assessments are objective, they will
overestimate the proportion of trials complying with CON-
SORT or TIDieR. Components 1) and 4) were judged as
reported if the name of the test (component 1) or treatment
(component 4) were given plus any one additional piece of
relevant information (for example the threshold for a test,
or a dose for a drug); articles providing only the name of
the test or treatment were considered as inadequately
reported. Components 2) and 3) were judged as present if
any information was given on decision-making (such as
how particular test results confer a particular diagnosis, or
how treatments were selected for different diagnoses).
Where trials contained a ‘no testing’ arm (for example,
comparing test driven therapy against empirical therapy)
only item 4) was recorded, items 1)-3) were coded as not
applicable. The numbers of reported items were compared
across test types and care settings.
Reports were also appraised for their use of diagrams
to explain the care pathway algorithms, following good
practice recommendations by the MRC for the evalu-
ation of complex interventions [32]. Diagrams were con-
sidered complete if they conveyed all four test-treatment
components for each trial arm, and partially reported if
at least one component was not represented in any trial
arm.
Extraction and quality assessment was performed
independently in duplicate by four authors (LFR, JD,
STP, JJD). Findings are described using percentages.
Results
The search strategy retrieved 12,892 citations (Table 1),
of which 1401 were screened in duplicate. Agreement
was substantial (k = 0.74), and full concordance results
have previously been published [29]. The final cohort
contained 103 trials comparing 105 control interventions
with 119 experimental interventions (Fig. 2).
Characteristics of trials
Trial reports were published in 70 journals, with only 21
journals publishing more than two. Most frequent jour-
nals were Radiology (n = 5), Health Technology Assessment
(n = 4), New England Journal of Medicine (n = 4), Human
Reproduction (n = 4), American Journal of Obstetrics and
Gynecology (n = 3), Journal of the American College of
Cardiology (n = 3), and Ultrasound in Obstetrics and
Gynecology (n = 3). Overall 66% (n = 68) were published in
specialist journals. Characteristics of the included studies
are summarized in Tables 2 and 3. A broad range of tech-
nologies were evaluated across 18 specialties, with imaging
the subject of evaluation in almost half the trials. Some
trials compared testing to no testing by evaluating the
benefits of removing testing from a previously tested
population (experimental ‘no test’ comparisons), or of
introducing a new test in a previously untested population
(control ‘no test’ comparisons).
Reporting of interventions
Trialists used between 34 and 1305 words (median: 336,
IQR: 153–560) to describe test-treatment interventions.
Descriptions of the clinical processes involved were
often poor, characterized by very low levels of detail and
frequently failing to report several test-treatment com-
ponents. Examples of well reported descriptions and our
judgements are provided in Table 4 [32–36].
Tests were the most commonly described component,
reported for over half of experimental strategies (64%,
74/115) though for little more than a third of control
groups (39%, 36/92) (Fig. 3). Diagnostic decision-making
criteria were mentioned in 49% (56/115) of experimental
and 34% (31/92) of control strategies, while management
decisions were mentioned in 45% (52/115) of experi-
mental and 33% (31/95) of control strategies. Treatment
interventions were the least frequently reported element,
outlined in only 21% (24/117) of experimental strategies,
and 16% (16/102) of control strategies.
All 4 components were missing from at least one arm
of 43 trials (42%), including 13 trials (13%) for which no
information was presented for any arm. Trials were
twice as likely to omit all description for control inter-
ventions (36%) than for experimental interventions
(18%) (Table 5). Thirteen percent (13/103) described all
four components of experimental interventions, and
11% (11/103) did so for control interventions. Only 5 of
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the 103 RCTs (5%) described all four test-treat compo-
nents for both control and experimental study arms.
Reports evaluating electrophysiological tests (e.g., car-
diotocography), clinical examinations and telemedical
consultations described the fewest components. Trials
that described control arms as ‘standard care’ reported
few of the required elements (Table 6). Reporting was
worse for test-treatment strategies conducted across
multiple care settings, though no difference was ob-
served between individual care sectors (Table 6). Trials
evaluating replacement testing strategies were less likely
to report at least 2 components (31/60, 52%) when com-
pared to those evaluating add-on (19/28, 68%) or triage
comparisons (13/17, 76%).
Use of care-pathway diagrams
Diagrams were included by approximately one-fifth of
trials, summarizing 20% (24/119) of experimental
interventions and 21% of (22/105) control interven-
tions. Care pathway diagrams were most informative
when they illustrated how patient management deci-
sions depended on the diagnostic findings. Fewer
Fig. 2 Identification of test-treatment RCTs from CENTRAL, searched 2009, Issue 2
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than 10% (8 experimental, 7 control) provided this
information.
Discussion
Key findings
In 98 (95%) of the 103 test-treatment RCTs, descriptions
of interventions did not mention all the components
necessary to characterize test-treatment strategies. Only
five trials (5%) provided a description of tests and test
methods, treatment methods and decision-making across
all study groups, none of which also provided a complete
care pathway diagram. We noted that test-treatment inter-
ventions for control groups were particularly poorly
reported. Descriptions of experimental interventions most
often provided details of tests, but less than half gave
details of diagnostic and management decision-making,
and less than a quarter mentioned which treatments were
subsequently used.
In many of these circumstances, failure to describe the
test-treatment interventions will make it impossible for
clinicians to assess whether the trial is applicable to their
practice, nor be able to implement the test-treatment
Table 2 Characteristics of included trials
Trial characteristics Total (N = 103) 2004–5 (N = 56) 2006–7 (N = 47)
n (%) n (%) n (%)
Trial design:
Parallel 90 (87) 49 (89) 41 (87)
Factorial 3 (3) 2 (4) 1 (2)
Cross-over 1 (1) 0 (−) 1 (2)
Randomized disclosure 9 (9) 5 (7) 4 (9)
Randomization:
Individual 97 (94) 53 (96) 44 (92)
Cluster 6 (6) 2 (4) 4 (8)
Number of study arms:
2 92 (89) 50 (91) 42 (88)
> 2 11 (11) 5 (9) 6 (13)
Diagnostic comparison:
Triage 17 (17) 9 (16) 8 (17)
Additional 28 (27) 15 (27) 13 (27)
Replacement 60 (58) 32 (57) 28 (58)
Medical Specialty:
Cardiovascular Medicine 35 (34) 20 (36) 15 (31)
Embryology 2 (2) 0 (−) 2 (4)
Emergency Medicine 1 (1) 0 (−) 1 (2)
Gastroenterology 14 (14) 6 (11) 8 (17)
General Medicine 1 (1) 0 (−) 1 (2)
Geriatrics 1 (1) 1 (2) 0 (−)
Infectious diseases 1 (1) 1 (2) 0 (−)
Neurology 3 (3) 1 (2) 2 (4)
Obstetrics and Gynecology 17 (17) 6 (11) 11 (23)
Oncology 5 (5) 5 (9) 0 (−)
Ophthalmology 2 (2) 2 (4) 0 (−)
Orthopedics 10 (10) 8 (15) 2 (4)
Otolaryngology 1 (1) 1 (2) 0 (−)
Psychiatry 2 (2) 0 (−) 2 (4)
Respiratory 3 (3) 1 (2) 2 (4)
Urology 2 (2) 1 (2) 1 (2)
Multiple 3 (3) 3 (5) 0 (−)
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intervention should they choose. The potential implica-
tions of such poor reporting is that the time and
resources invested in these trials may be largely wasted
[37].
Interpretation of findings
Our study is the first to analyze the reporting quality of
interventions in RCTs of test-treatment strategies. Other
studies evaluating the reporting quality of complex inter-
ventions have noted inadequate descriptions of
interventions in 87% of back-pain RCTs [38], 59% of surgi-
cal treatment trials [5] and 61% of non-pharmacological
intervention RCTs [4]. Our finding that test-treatment
strategies are inadequately described by 95% of trials sug-
gests that there are additional challenges to describing these
interventions. We present three explanations for our
findings.
First, many trials have used an approach that solely
specifies a new test in the study arm against a control
arm of standard care, without providing any further
specification of the test-treatment intervention in either
arm. Overall 24% (25/103) of trials reported only the
tests used in the different arms, while 8 of the 10 trials
comparing new tests against a control arm of standard
care failed to specify the tests or any subsequent details
of management and treatment in the control arm. For
example, a trial of routine lumbar X-ray in patients with
acute lower back pain (LBP) simply described the inter-
ventions as: “In addition to receiving the usual care for
patients with LBP, the intervention group patients had
lumbar spine radiography at the baseline interview. The
control group received the usual care without lumbar
spine radiography” [39]. These trials typically neither
specified nor recorded how test results were used for
decision-making, what pathologies were diagnosed, or
what treatments were actually used.
Secondly, test-treatment pathways may be difficult to
describe, or even enumerate, due to the myriad of possible
Table 4 Definition of the four components used to assess the description of test-treatment interventions, with examples of
adequate descriptions
Component Definition and example
1. Diagnostic test: Technique used to perform the test. Reporting the name of the test only was considered insufficient.
e.g., “Radiographs of the knee were obtained in the lateral and anteroposterior projection and were
supplemented with patellar or tunnel views if pathologic abnormalities of the patellofemoral joint or
intercondylar notch were suspected” [33].
2. Diagnostic decision: Description of the operational criteria used for arriving at a particular diagnosis using the test results.
e.g., “If the lung scan showed no abnormalities, pulmonary embolism was excluded; if there were 1 or more
segmental perfusion defects that were normally ventilated, the scan was considered diagnostic for pulmonary
embolism (“high-probability scan”); and if there were perfusion defects that did not meet criteria for a
“high-probability scan,” the scan was considered nondiagnostic” [34].
3. Management decision: Description of how treatments were selected as a result of the diagnosis.
e.g., “Patients in group A1 and group A2 with H. pylori sensitive to AMO and LEV were treated with AMO (1 g
b.i.d.), LEV (500 mg b.i.d.), and ESO (esomeprazole) (20 mg b.i.d.) for 10 days. If H. pylori was found resistant to
AMO and/or LEV the treatment was based on the indications of the susceptibility test. Patients enrolled in group
B1 and group B2 were treated empirically, that is without performing the H. pylori susceptibility to various
antibiotics, with a standard treatment that included AMO (1 g b.i.d.), LEV (500 mg b.i.d.), and ESO (20 mg b.i.d.)
for 10 days” [35].
4. Treatment: Description of how selected treatments were administered. Reporting of the treatment name only was
considered insufficient.
e.g., “After ultrasound diagnosis of an anal sphincter tear… women were brought immediately to the operating
room to provide appropriate lighting, instruments, and assistants and underwent a surgical exploration of the
perineum by the obstetrician-in-charge under senior supervision. The anal sphincter was exposed and its integrity
assessed by inspection and palpation. The ends of the sphincter were approximated end-to-end with 2–0
monofilament polyglyconate sutures (Maxon, Sherwood Davis & Geck, St. Louis, MO). Postoperatively, women
received dietary advice to avoid constipation, with occasional use of stool softeners. For women allocated to the
control group, the obstetrician sutured the perineum after clinical examination” [36].
Table 3 Test types evaluated in the 103 test-treatment RCTs
Test type Control (%) Experimental (%)
Biochemical 10 (10) 25 (21)
Biopsy 1 (1) 2 (2)
Clinical 18 (17) 14 (12)
Electrophysiology 7 (7) 10 (8)
Imaging (all) 35 (33) 50 (42)
Endoscopy 14 (13) 11 (9)
Radiology 21 (20) 39 (33)
Telemedicine 2 (2) 2 (2)
Standard Care 10 (10) 0 (0)
Multiple test interventions 8 (8) 12 (10)
No test 14 (13) 4 (3)
Total a105 a119
adenominators refer to the number of study arms
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downstream actions following a test. We know from
trials of complex therapeutic interventions that
decision-making processes are very difficult to circum-
scribe into standardized, rigid protocols, and these
problems could account for the poor descriptions we
observed of clinical examinations, tele-medical consul-
tations and multiple-test interventions (Table 5). On
the other hand we found complex endoscopic tech-
niques were often standardized and well described,
despite often being part of multistage diagnostic
processes.
Finally, the link between better reporting of experi-
mental and control interventions in a minority of
studies suggests there is a lack of awareness amongst
trialists and investigators of the level of detail which
needs to be included in a trial report. Journal instruc-
tions to authors of trial reports have been found
lacking, with only 14% (15/106) providing specific
directives regarding the reporting of interventions [40].
Thus the need to describe several components of multi-
stage complex interventions is likely to be more poorly
recognized.
Requirements for pragmatic RCTs of test-treatment
interventions
There is general acceptance that results of pragmatic trials
are more applicable to standard practice than explanatory
trials [41]. We did not formally assess the position of our
trials on the pragmatic explanatory continuum [42],
however all the studies we examined were undertaken
in the ‘real world’ and evaluated the impact of new
testing strategies, alongside current practice, on patient
health. We would argue that the notion of ‘explanatory’
trials does not apply well to test-treatment RCTs seeking
to evaluate downstream health consequences, but rather
best describes studies such as those evaluating diagnostic
accuracy (‘does the new test correctly discriminate
between diseased and non-diseased patients?’). For a test-
treatment RCT, undertaking a pragmatic approach in-
volves recruiting patients as they present in standard care,
utilizing tests and treatments as would be provided in the
health service, and allowing flexibility to tailor interven-
tions to individual patients as would occur in practice
(including allowance of non-compliance, cross-overs and
drop-outs). Nevertheless, guidance for pragmatic trials
Table 5 Reporting of control vs. experimental interventions
Number of
components
reported
aControl interventions aExperimental interventions bControl arm per trial bExperimental arm per trial
n (%) n (%) n (%) n (%)
0 38 (36) 24 (20) 37 (36) 19 (18)
1 19 (18) 25 (21) 19 (18) 22 (21)
2 21 (20) 29 (24) 20 (19) 26 (25)
3 16 (15) 27 (23) 16 (16) 23 (22)
4 11 (10) 14 (12) 11 (11) 13 (13)
Total 105 (100) 119 (100) 103 (100) 103 (100)
Table presents counts of the number of individual interventions (n = 224) and total number of included trials (N = 103) that reported between zero and all four
components of test-treatment interventions. Items deemed not applicable were counted as reported
aNumber of study arms reporting 0–4 components
bNumber of trials reporting 0–4 components in at least one study arm (some trials evaluated multiple control and/or experimental groups)
Fig. 3 Proportion of trial arms describing each element of the test-treatment protocol. Some strategies did not require description of a test or treatment
(or associated decision-making), for example when evaluating the addition of a new test to no test, or the removal of treatment.
Denominators differed when test-treat strategies did not involve a test or a treatment (e.g., trials comparing the benefits of treating all
vs. testing to select those for treatment [45]). The denominators for frequency calculations were reduced accordingly: Diagnostic method:
Experimental n = 115, Control n = 92. Diagnostic decision: Experimental n = 115, Control n = 92. Treatment decision: Experimental n = 115,
Control n = 95. Treatment method: Experimental n = 117, Control n = 102
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clearly states that the intended interventions in all arms
should be defined precisely [43, 44].
Findings from a new test are most likely to be used in
an effective way if information on their diagnostic value,
and guidance on how they should impact on management,
are provided. This is particularly important for new test
technologies, where clinicians may be unsure about basing
management decisions on new diagnostic information
and, in the absence of guidance, could ignore results of
the new test or respond to it in inconsistent ways; both
would bias studies towards finding no difference.
The absence of complete description of the interven-
tions in the majority of studies might have arisen from
poor reporting, but also because the trial protocols may
never have specified how test results were to be interpreted
and used to determine treatment. Such an approach could
have arisen if trialists wrongly considered it to be appropri-
ate in a pragmatic trial design. Other possible explanations
include challenges in documenting the components in the
test-treatment intervention; concern that specifying a par-
ticular care pathway may limit recruitment; or in some
circumstances uncertainty around how the results of a test
could be best used to determine treatment. Greater
preparatory work to fully develop and specify the test-
treatment intervention, and obtain buy-in from clinicians
involved in the trial, might solve these issues. An RCT of a
test strategy that commences before it is determined how
test results should be used could ultimately reflect variation
in clinician behavior more than the potential value of a
diagnostic technology.
There are arguments against specifying control test-
treatment strategies in trials whose explicit purpose is to
compare outcomes from organized diagnostic services with
unstructured care (14 examples were found in our cohort).
Since this comparison is of a formalized diagnostic strategy
against an approach allowing a clinician to operate without
guidance, it is clear that introducing a protocol for
decision-making in the control arm would eliminate any
effect.
Good pragmatic trials of test-treatment interventions
should also report the diagnoses made and treatments
undertaken in each arm of the trial, delineated by test
results so that one can assess the degree of adherence to
the recommended test-treatment protocols. Whilst several
studies reported measures of diagnostic and therapeutic
impact aggregated in each trial arm, it was very rare for
this to be presented according to the test result.
Recommendations
We make three recommendations. First, reporting can
be improved by providing guidance for authors. The
TIDieR checklist provides a useful tool to assist in
describing interventions, but does not explicitly consider
complex “staged” interventions such as test-treatment
Table 6 Reporting of control vs. experimental interventions
Trial characteristic Control (N = 105) Experimental (N = 119) Total (N = 224)
>2 components reported (%) >2 components reported (%) >2 components reported (%)
Test type:
Biochemical 3 (30) 10 (40) 13 (37)
Biopsy 0 (−) 1 (50) 1 (33)
Clinical 2 (11) 6 (43) 8 (25)
Electrophysiology 2 (29) 1 (10) 3 (18)
Imaging (all) 6 (17) 17 (34) 23 (27)
Endoscopy 2 (14) 5 (45) 7 (28)
Radiology 4 (19) 12 (31) 16 (27)
No test 12 (86) 4 (100) 16 (89)
Standard Care 1 (10) 0 (−) 1 (10)
Telemedicine 0 (−) 0 (−) 0 (−)
Multiple 2 (25) 2 (17) 4 (20)
Care sector:
Emergency 3 (25) 5 (42) 8 (33)
Primary 4 (36) 10 (56) 14 (48)
Secondary 9 (20) 12 (24) 21 (22)
Tertiary 12 (43) 13 (43) 25 (43)
Multiple 0 (−) 1 (13) 1 (6)
Total 28 (27) 41 (34) 69 (31)
Table presents counts of the number of individual interventions for which 3 or more test-treatment components were reported
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trials. These require further development of Item 9 in
TIDieR (handling the tailoring of interventions that are
not identical for all participants, which requires descrip-
tions of “how, why, what and when interventions are
personalized, titrated or adapted”) [11]. The current tool
does not highlight that this should include a full delinea-
tion of all management pathways according to test results
in test-treatment comparisons. These might best be sum-
marized graphically in a decision-tree which outlines the
different sets of test results, the diagnoses which can be
made from them, and the possible actions which could
occur at each step, as illustrated in Fig. 4. In future,
additional detail might be provided in ‘diagnostic interven-
tion manuals’, mirroring complex intervention practice,
although such an approach should first be investigated to
ensure it provides a useful addition to intervention
description.
Second, all trials must aim to prescribe the diagnostic
strategies and care pathways that should be followed and
describe them in adequate detail to allow replication.
Whilst trials evaluating highly flexible interventions allow
deviation from planned care pathways as clinically re-
quired, the pathways should be specified with as much de-
tail as possible in the study protocol and report. For highly
variable diagnostic strategies that are difficult to translate
into a prescriptive format, such as clinical consultations,
trialists should as a minimum aim to standardize the
intended function of the tests [45], by pre-specifying diag-
nostic goals that can be modified at a local level to suit
organizational differences.
Fig. 4 Example of a decision-tree graphic summarizing the 4 key components of one test-treatment intervention. Developed to illustrate
an intervention evaluated in a published RCT [46]
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Third, reports should describe the care pathways actually
followed during the trial, delineating decisions according to
the test results and not simply aggregated by study arm.
This will be particularly important in pragmatic trials to de-
scribe any deviations from the pathway. Embedding process
evaluations that measure how interventions are actually
administered within a trial [32] may help conceptualize the
way in which tests are being used.
We would highlight the need for research on methods
of reporting care pathways, variability of care pathways
in different settings, and barriers to changing the path-
ways. Particularly there needs to be an assessment of the
information that needs to be reported in a care pathway
description to enable its replication in a new setting, and
the degree of variability that would be acceptable in
pragmatic trials.
Strengths and limitations
Our study is the first to systematically identify an
unselected group of test-treatment RCTs, and assess
the quality of intervention reporting. Our cohort
includes diverse test-treat interventions, conducted
in a wide range of medical settings and specialties.
Reporting judgements have been made in duplicate
using a standardized extraction tool and disagree-
ments discussed.
We chose to assess whether any detail was mentioned,
and not to assess whether the description was adequate
to allow the intervention to be replicated (as recom-
mended by the TIDieR checklist), or whether specific
features (such as care-provider skill and experience [46])
were detailed. This decision was made to ensure our as-
sessments were objective and because of the challenge
in identifying experts able to make judgements across
the wide range of settings and specialties in the cohort.
Even fewer studies than we report are likely to have re-
ported interventions with adequate detail to allow their
replication, including information adequate to establish
the appropriateness of care-provider skill used.
The scant reporting we have found certainly reflects
inadequate reporting of test-treatment interventions,
however it is important that future research investigates
the extent to which this may be caused by inadequate
trial conduct. This could be achieved by contacting trial
authors.
Our trials are from a cohort we have previously
reported [23, 29] and were published from 2004 to 7,
after publication of the CONSORT 2001 statement but
before the CONSORT 2010 and SPIRIT guidelines. It is
possible that the reporting of some aspects of the meth-
odology of trials has improved over recent years, par-
ticularly given the publication of guidelines for reporting
and conducting diagnostic accuracy studies; however
any such improvement in describing test-treatment
interventions is unlikely to be dramatic since neither
CONSORT 2010, STARD 2015, nor any other published
standards have addressed test-treatment strategies. Since
our sample of trials was ascertained from searching
CENTRAL, which indexes relevant studies found in
MEDLINE, EMBASE and other specialist registers, it is
possible that we have missed eligible test-treatment trials
not indexed in these resources. It is arguable, however,
that such trials would have changed our findings consider-
ably since in order to have escaped detection by our search
of the major databases they are likely to have been more
poorly reported [29].
Conclusions
This review identifies a clear need for improvement in
the reporting of interventions in test-treatment trials.
Descriptions were so poor that most trial reports we
examined are of limited use: their results cannot be
interpreted since it is unclear which tests are being eval-
uated, how these tests are used to inform management,
or how treatments are subsequently administered. Since
these details are needed to reproduce interventions as
safely and effectively as claimed, published trial reports
are currently unlikely to enable users to translate inter-
ventions into practice. The failure in some pragmatic
trials to define how tests should be interpreted and used
to direct treatment decisions risks trials failing to dem-
onstrate intended effects due to inadequate implementa-
tion, rather than true ineffectiveness.
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